Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 3/20 | 0.50 |
| ▸ | BRAF | P15056 | 7/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984127 | 0.87 | GPR52 (0.52) | GPR52BRAFNR3C2MAPK14KDR | |
| SCHEMBL14273260 | 0.86 | GPR52 (0.49) | GPR52NR3C2MAPK14PPARGPPARD | |
| SCHEMBL3986272 | 0.85 | NR3C2 (0.45) | GPR52BRAFNR3C2MAPK14KDR | |
| SCHEMBL5115943 | 0.82 | BRAF (0.44) | GPR52BRAFNR3C2KDR | |
| SCHEMBL5129564 | 0.82 | GPR52 (0.44) | GPR52BRAFMAPK14KDRPPARG | |
| SCHEMBL3983997 | 0.80 | KDR (0.51) | GPR52KDRPPARGPPARDPPARA | |
| SCHEMBL4293095 | 0.79 | GRM5 (0.49) | BRAFNR3C2 | |
| SCHEMBL4115551 | 0.79 | BRAF (0.50) | GPR52BRAFNR3C2MAPK14KDR | |
| SCHEMBL3994618 | 0.79 | RAF1 (0.54) | BRAFKDR | |
| SCHEMBL3991944 | 0.79 | GRM5 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061761-A1 | PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | Millennium Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2008030448-A1 | PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MAP4K5, MAP3K5, MAP4K2 | GPR52 1892/4885BRAF 242/4885NR3C2 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.